// App-Quantinova.ai

: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

Researchers

Presenter

  • Matt D. Galsky

Principal Investigators

  • Maria De Santis

  • Ian D. Davis

  • Aristotelis Bamias

  • Eiji Kikuchi

  • Xavier Garcia del Muro

  • Se Hoon Park

  • Ugo De Giorgi

  • Boris Alekseev

  • Marina Mencinger

  • Kouji Izumi

  • Javier Puente

  • Jian-Ri Li

  • Peter H. O'Donnell

  • Sandrine Bernhard

  • Chooi Peng Lee

  • Fabiola Bene-Tchaleu

  • Sanjeev Mariathasan

  • Enrique Grande

Medical Centers

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • MD Anderson Cancer Center, Madrid, Spain

  • Eastern Health Clinical School, Monash University, Melbourne, Australia

  • Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain

  • Institute of Oncology Ljubljana, Ljubljana, Slovenia

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain

  • Genentech, Inc., South San Francisico, CA

  • Kanazawa University, Kanazawa, Japan

  • St. Marianna University, Kawasaki, Japan

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • Taichung Veterans General Hospital, Taichung City, Taiwan

  • Research Oncology Institute, Tomsk, Russian Federation

  • Charité University Hospital, Department of Urology, Berlin, Germany, and Medical University, Department of Urology, Vienna, Austria

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • The University of Chicago Medical Center, Chicago, IL

  • National and Kapodistrian University of Athens, Athens, Greece

Locations

  • Russia

  • Republic of South Korea

  • Italy

  • Canada

  • Slovenia

  • Japan

  • Austria

  • Spain

  • Australia

  • Greece

  • United Kingdom

  • Taiwan

  • United States

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02807636

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved